Cargando…
Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease
For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device‐based cognitive tools are converting classically noisy, su...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052022/ https://www.ncbi.nlm.nih.gov/pubmed/26272508 http://dx.doi.org/10.1002/cpt.212 |
_version_ | 1782458174674042880 |
---|---|
author | Leurent, C Ehlers, MD |
author_facet | Leurent, C Ehlers, MD |
author_sort | Leurent, C |
collection | PubMed |
description | For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device‐based cognitive tools are converting classically noisy, subjective, data‐poor clinical endpoints associated with neuropsychiatric disease assessment into a richer, scalable, and objective set of measurements. Incorporation of such endpoints into clinical drug trials holds promise for more quickly and efficiently developing new medicines. |
format | Online Article Text |
id | pubmed-5052022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50520222016-10-06 Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease Leurent, C Ehlers, MD Clin Pharmacol Ther Development For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device‐based cognitive tools are converting classically noisy, subjective, data‐poor clinical endpoints associated with neuropsychiatric disease assessment into a richer, scalable, and objective set of measurements. Incorporation of such endpoints into clinical drug trials holds promise for more quickly and efficiently developing new medicines. John Wiley and Sons Inc. 2015-09-08 2015-11 /pmc/articles/PMC5052022/ /pubmed/26272508 http://dx.doi.org/10.1002/cpt.212 Text en © 2015 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of The American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Development Leurent, C Ehlers, MD Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease |
title | Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease |
title_full | Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease |
title_fullStr | Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease |
title_full_unstemmed | Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease |
title_short | Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease |
title_sort | digital technologies for cognitive assessment to accelerate drug development in alzheimer's disease |
topic | Development |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052022/ https://www.ncbi.nlm.nih.gov/pubmed/26272508 http://dx.doi.org/10.1002/cpt.212 |
work_keys_str_mv | AT leurentc digitaltechnologiesforcognitiveassessmenttoacceleratedrugdevelopmentinalzheimersdisease AT ehlersmd digitaltechnologiesforcognitiveassessmenttoacceleratedrugdevelopmentinalzheimersdisease |